Literature DB >> 24399318

Cloning and expression of the functional human anti-vascular endothelial growth factor (VEGF) using the pcDNA3.1 vector and the human chronic myelogenous leukemia cell line K562.

Masoumeh Hajirezaei1, Mojtaba Darbouy, Bahram Kazemi.   

Abstract

In this study, the light chain (κ) and heavy chain (γ) sequences of the monoclonal antibody against vascular endothelial growth factor (VEGF) were sub-cloned into the eukaryotic pcDNA3.1 (+) (Hygro) and the pcDNA3.1 (+) (Neo) expression vectors using the traditional and homologous recombination methods. To express the antibody, the recombinant plasmids were transfected into the Chinese hamster ovary (CHO) and the K562 cell lines. The recombinant antibody was then purified using the protein A affinity chromatography. Furthermore, in order to demonstrate the inhibition of VEGF-induced mitogenesis of the recombinant antibody, the bovine aorta endothelial like cells were employed. The results showed specialization and conjunction of the recombinant antibody to the VEGF. It was also indicated that the antibody expression in the K562 cell lines was higher than the CHO cell lines. Furthermore, the in vitro VEGF inhabitation of the recombinant antibodies which were produced from the K562 cell line, and the CHO cell line, were similar. This proved that the K562 cell line is a good substitute for the CHO cell line in the production of the recombinant antibodies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24399318     DOI: 10.1007/s10930-013-9533-y

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  53 in total

Review 1.  Endothelial signal integration in vascular assembly.

Authors:  T O Daniel; D Abrahamson
Journal:  Annu Rev Physiol       Date:  2000       Impact factor: 19.318

2.  Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells.

Authors:  H R Kim; H S Kang; H D Kim
Journal:  IUBMB Life       Date:  1999-10       Impact factor: 3.885

Review 3.  Structure, expression and receptor-binding properties of novel vascular endothelial growth factors.

Authors:  U Eriksson; K Alitalo
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

Review 4.  VEGF: an update on biological and therapeutic aspects.

Authors:  N Ferrara
Journal:  Curr Opin Biotechnol       Date:  2000-12       Impact factor: 9.740

Review 5.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

Review 6.  Regulation of tumor growth and metastasis by thrombospondin-1.

Authors:  D D Roberts
Journal:  FASEB J       Date:  1996-08       Impact factor: 5.191

Review 7.  Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.

Authors:  Roy S Herbst; Corey J Langer
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

8.  Parameters affecting the frequencies of transformation and co-transformation with synthetic oligonucleotides in yeast.

Authors:  T Yamamoto; R P Moerschell; L P Wakem; D Ferguson; F Sherman
Journal:  Yeast       Date:  1992-11       Impact factor: 3.239

9.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

Authors:  E R Horak; R Leek; N Klenk; S LeJeune; K Smith; N Stuart; M Greenall; K Stepniewska; A L Harris
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

Review 10.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.